Nonavalent HPV vaccine vs quadrivalent HPV vaccine
Serious adverse events at up to 4.5‐year · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in serious adverse events at up to 4.5‐year compared with quadrivalent HPV vaccine (low certainty).
1 finding from 1 review
- Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related… 2019 · Cochrane Headline outcomes onlyOR 0.6 [0.14, 2.61]3 studies · 15863 participantsLow